factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 1974-1985 | 1974-1985 | T119 | exacerbated | AFFECTS | 1,974 | 1,985 | preserve | 2001-2005 | 2001-2005 | T116 | diet | Food | 2,001 | 2,005 | preserve | 1961-1973 | 1961-1973 | T113 | hypertension | DiseaseOrSyndrome | 1,961 | 1,973 | A10 | These data indicate that the chronic depressor actions of metformin are enhanced in animals with hypertension exacerbated by a high-salt diet. | 1852-2006 | 1,852 | 2,006 | These data indicate that the chronic depressor actions of metformin are enhanced in animals with @OBJECT$ @PREDICAT$ by a high-salt @SUBJECT$ . |
Fact | preserve | 10-20 | 10-20 | T6 | attenuates | TREATS | 10 | 20 | preserve | 0-9 | 0-9 | T1 | Metformin | OrganicChemical | 0 | 9 | preserve | 34-46 | 34-46 | T4 | hypertension | DiseaseOrSyndrome | 34 | 46 | A11 | Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats. | 0-88 | 0 | 88 | @SUBJECT$ @PREDICAT$ salt-induced @OBJECT$ in spontaneously hypertensive rats. |
Fact | preserve | 136-145 | 136-145 | T16 | treatment | TREATS | 136 | 145 | preserve | 89-98 | 89-98 | T8 | Metformin | OrganicChemical | 89 | 98 | preserve | 149-179 | 171-179 | T12 | type 2 diabetes mellitus | DiseaseOrSyndrome | 149 | 179 | A12 | Metformin, an antihyperglycemic agent used for treatment of type 2 diabetes mellitus, lowers blood pressure in humans and experimental animals. | 89-238 | 89 | 238 | @SUBJECT$ , an antihyperglycemic agent used for @PREDICAT$ of @OBJECT$ , lowers blood pressure in humans and experimental animals. |
Probable | preserve | 318-323 | 318-323 | T24 | lower | INHIBITS | 318 | 323 | preserve | 304-313 | 304-313 | T20 | metformin | OrganicChemical | 304 | 313 | preserve | 324-338 | 330-338 | T21 | blood pressure | Finding | 324 | 338 | A14 | We recently demonstrated that short-term administration of metformin may lower blood pressure by reducing sympathetic neural outflow. | 239-384 | 239 | 384 | We recently demonstrated that short-term administration of @SUBJECT$ may @PREDICAT$ @OBJECT$ by reducing sympathetic neural outflow. |
Fact | preserve | 1688-1692 | 1688-1692 | T87 | with | PROCESS_OF | 1,688 | 1,692 | preserve | 1693-1711 | 1704-1711 | T85 | autoimmune disease | DiseaseOrSyndrome | 1,693 | 1,711 | preserve | 1679-1687 | 1679-1687 | T84 | patients | PatientOrDisabledGroup | 1,679 | 1,687 | A2 | Instead, costimulatory activity of CD44v7 was seen only in PBMC of patients with autoimmune disease and IBD. | 1606-1727 | 1,606 | 1,727 | Instead, costimulatory activity of CD44v7 was seen only in PBMC of @OBJECT$ @PREDICAT$ @SUBJECT$ and IBD. |
Fact | preserve | 598-602 | 598-602 | T39 | with | PROCESS_OF | 598 | 602 | preserve | 617-624 | 617-624 | T34 | disease | DiseaseOrSyndrome | 617 | 624 | preserve | 589-597 | 589-597 | T33 | patients | PatientOrDisabledGroup | 589 | 597 | A4 | Expression of CD44 variant isoforms (CD44v) has been evaluated on PBMC of 46 patients with IBD, 43 patients with autoimmune diseases not affecting the gastrointestinal tract, 26 patients with nonautoimmune disease, and 24 healthy donors. | 399-654 | 399 | 654 | Expression of CD44 variant isoforms (CD44v) has been evaluated on PBMC of 46 patients with IBD, 43 patients with autoimmune diseases not affecting the gastrointestinal tract, 26 @OBJECT$ @PREDICAT$ nonautoimmune @SUBJECT$ , and 24 healthy donors. |
Fact | preserve | 1782-1786 | 1782-1786 | T103 | with | PROCESS_OF | 1,782 | 1,786 | preserve | 1825-1828 | 1825-1828 | T94 | IBD | DiseaseOrSyndrome | 1,825 | 1,828 | preserve | 1773-1781 | 1773-1781 | T91 | patients | PatientOrDisabledGroup | 1,773 | 1,781 | A5 | Because expression and function of CD44v7 in patients with systemic autoimmune disease and IBD have been much like the ones in mice suffering of TNBS-induced colitis, it is tempting to speculate that blockade of CD44v7 could also be of therapeutic relevance in the human diseases. | 1728-2026 | 1,728 | 2,026 | Because expression and function of CD44v7 in @OBJECT$ @PREDICAT$ systemic autoimmune disease and @SUBJECT$ have been much like the ones in mice suffering of TNBS-induced colitis, it is tempting to speculate that blockade of CD44v7 could also be of therapeutic relevance in the human diseases. |
Fact | preserve | 925-929 | 925-929 | T55 | with | PROCESS_OF | 925 | 929 | preserve | 930-948 | 941-948 | T52 | autoimmune disease | DiseaseOrSyndrome | 930 | 948 | preserve | 916-924 | 916-924 | T51 | patients | PatientOrDisabledGroup | 916 | 924 | A6 | Exclusively on PBMC of patients with autoimmune disease, high expression of CD44v3 and CD44v7 was observed. | 893-1006 | 893 | 1,006 | Exclusively on PBMC of @OBJECT$ @PREDICAT$ @SUBJECT$ , high expression of CD44v3 and CD44v7 was observed. |
Fact | preserve | 1456-1460 | 1456-1460 | T77 | with | PROCESS_OF | 1,456 | 1,460 | preserve | 1467-1485 | 1478-1485 | T75 | autoimmune disease | DiseaseOrSyndrome | 1,467 | 1,485 | preserve | 1447-1455 | 1447-1455 | T74 | patients | PatientOrDisabledGroup | 1,447 | 1,455 | A7 | This was irrespective of whether the PBMC were derived from healthy donors or from patients with autoimmune disease or IBD. | 1358-1493 | 1,358 | 1,493 | This was irrespective of whether the PBMC were derived from healthy donors or from @OBJECT$ @PREDICAT$ @SUBJECT$ or IBD. |
Fact | preserve | 1866-1875 | 1866-1875 | T105 | suffering | PROCESS_OF | 1,866 | 1,875 | preserve | 1898-1905 | 1898-1905 | T98 | colitis | DiseaseOrSyndrome | 1,898 | 1,905 | preserve | 1861-1865 | 1861-1865 | T96 | mice | Mammal | 1,861 | 1,865 | A9 | Because expression and function of CD44v7 in patients with systemic autoimmune disease and IBD have been much like the ones in mice suffering of TNBS-induced colitis, it is tempting to speculate that blockade of CD44v7 could also be of therapeutic relevance in the human diseases. | 1728-2026 | 1,728 | 2,026 | Because expression and function of CD44v7 in patients with systemic autoimmune disease and IBD have been much like the ones in @OBJECT$ @PREDICAT$ of TNBS-induced @SUBJECT$ , it is tempting to speculate that blockade of CD44v7 could also be of therapeutic relevance in the human diseases. |
Fact | preserve | 513-517 | 513-517 | T38 | with | PROCESS_OF | 513 | 517 | preserve | 518-537 | 529-537 | T30 | autoimmune diseases | DiseaseOrSyndrome | 518 | 537 | preserve | 504-512 | 504-512 | T29 | patients | PatientOrDisabledGroup | 504 | 512 | A10 | Expression of CD44 variant isoforms (CD44v) has been evaluated on PBMC of 46 patients with IBD, 43 patients with autoimmune diseases not affecting the gastrointestinal tract, 26 patients with nonautoimmune disease, and 24 healthy donors. | 399-654 | 399 | 654 | Expression of CD44 variant isoforms (CD44v) has been evaluated on PBMC of 46 patients with IBD, 43 @OBJECT$ @PREDICAT$ @SUBJECT$ not affecting the gastrointestinal tract, 26 patients with nonautoimmune disease, and 24 healthy donors. |
Fact | preserve | 491-495 | 491-495 | T37 | with | PROCESS_OF | 491 | 495 | preserve | 496-499 | 496-499 | T28 | IBD | DiseaseOrSyndrome | 496 | 499 | preserve | 482-490 | 482-490 | T27 | patients | PatientOrDisabledGroup | 482 | 490 | A11 | Expression of CD44 variant isoforms (CD44v) has been evaluated on PBMC of 46 patients with IBD, 43 patients with autoimmune diseases not affecting the gastrointestinal tract, 26 patients with nonautoimmune disease, and 24 healthy donors. | 399-654 | 399 | 654 | Expression of CD44 variant isoforms (CD44v) has been evaluated on PBMC of 46 @OBJECT$ @PREDICAT$ @SUBJECT$ , 43 patients with autoimmune diseases not affecting the gastrointestinal tract, 26 patients with nonautoimmune disease, and 24 healthy donors. |
Fact | preserve | 42-44 | 42-44 | T9 | in | ASSOCIATED_WITH | 42 | 44 | preserve | 0-4 | 0-4 | T1 | CD44 | GeneOrGenome | 0 | 4 | preserve | 53-79 | 72-79 | T5 | inflammatory bowel disease | DiseaseOrSyndrome | 53 | 79 | A12 | CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. | 0-125 | 0 | 125 | @SUBJECT$ variant isoforms on blood leukocytes @PREDICAT$ chronic @OBJECT$ and other systemic autoimmune diseases. |
Fact | preserve | 1456-1460 | 1456-1460 | T77 | with | PROCESS_OF | 1,456 | 1,460 | preserve | 1489-1492 | 1489-1492 | T76 | IBD | DiseaseOrSyndrome | 1,489 | 1,492 | preserve | 1447-1455 | 1447-1455 | T74 | patients | PatientOrDisabledGroup | 1,447 | 1,455 | A14 | This was irrespective of whether the PBMC were derived from healthy donors or from patients with autoimmune disease or IBD. | 1358-1493 | 1,358 | 1,493 | This was irrespective of whether the PBMC were derived from healthy donors or from @OBJECT$ @PREDICAT$ autoimmune disease or @SUBJECT$ . |
Fact | preserve | 22-24 | 22-24 | T8 | on | LOCATION_OF | 22 | 24 | preserve | 25-41 | 31-41 | T3 | blood leukocytes | Cell | 25 | 41 | preserve | 0-4 | 0-4 | T1 | CD44 | GeneOrGenome | 0 | 4 | A15 | CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. | 0-125 | 0 | 125 | @OBJECT$ variant isoforms @PREDICAT$ @SUBJECT$ in chronic inflammatory bowel disease and other systemic autoimmune diseases. |
Fact | preserve | 1688-1692 | 1688-1692 | T87 | with | PROCESS_OF | 1,688 | 1,692 | preserve | 1723-1726 | 1723-1726 | T86 | IBD | DiseaseOrSyndrome | 1,723 | 1,726 | preserve | 1679-1687 | 1679-1687 | T84 | patients | PatientOrDisabledGroup | 1,679 | 1,687 | A16 | Instead, costimulatory activity of CD44v7 was seen only in PBMC of patients with autoimmune disease and IBD. | 1606-1727 | 1,606 | 1,727 | Instead, costimulatory activity of CD44v7 was seen only in PBMC of @OBJECT$ @PREDICAT$ autoimmune disease and @SUBJECT$ . |
Fact | preserve | 42-44 | 42-44 | T9 | in | ASSOCIATED_WITH | 42 | 44 | preserve | 0-4 | 0-4 | T1 | CD44 | GeneOrGenome | 0 | 4 | preserve | 105-124 | 116-124 | T7 | autoimmune diseases | DiseaseOrSyndrome | 105 | 124 | A17 | CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases. | 0-125 | 0 | 125 | @SUBJECT$ variant isoforms on blood leukocytes @PREDICAT$ chronic inflammatory bowel disease and other systemic @OBJECT$ . |
Fact | preserve | 1342-1350 | 1342-1350 | T71 | produced | PRODUCES | 1,342 | 1,350 | preserve | 1336-1341 | 1336-1341 | T69 | cells | Cell | 1,336 | 1,341 | preserve | 1351-1356 | 1351-1356 | T70 | IL-10 | AminoAcidPeptideOrProtein | 1,351 | 1,356 | A18 | After culturing PBMC in the presence of anti-CD44v7, a higher percentage of cells produced IL-10. | 1253-1357 | 1,253 | 1,357 | After culturing PBMC in the presence of anti-CD44v7, a higher percentage of @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 389-393 | 389-393 | T23 | with | PROCESS_OF | 389 | 393 | preserve | 394-397 | 394-397 | T22 | IBD | DiseaseOrSyndrome | 394 | 397 | preserve | 380-388 | 380-388 | T21 | patients | PatientOrDisabledGroup | 380 | 388 | A19 | This finding led us to evaluate whether CD44v7 may be of functional importance in patients with IBD. | 292-398 | 292 | 398 | This finding led us to evaluate whether CD44v7 may be of functional importance in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 2011-2025 | 2017-2025 | T106 | human diseases | PROCESS_OF | 2,011 | 2,025 | preserve | 2017-2025 | 2017-2025 | T101 | diseases | DiseaseOrSyndrome | 2,017 | 2,025 | preserve | 2011-2016 | 2011-2016 | T100 | human | Human | 2,011 | 2,016 | A20 | Because expression and function of CD44v7 in patients with systemic autoimmune disease and IBD have been much like the ones in mice suffering of TNBS-induced colitis, it is tempting to speculate that blockade of CD44v7 could also be of therapeutic relevance in the human diseases. | 1728-2026 | 1,728 | 2,026 | Because expression and function of CD44v7 in patients with systemic autoimmune disease and IBD have been much like the ones in mice suffering of TNBS-induced colitis, it is tempting to speculate that blockade of CD44v7 could also be of therapeutic relevance in the @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1782-1786 | 1782-1786 | T103 | with | PROCESS_OF | 1,782 | 1,786 | preserve | 1787-1820 | 1813-1820 | T93 | systemic autoimmune disease | DiseaseOrSyndrome | 1,787 | 1,820 | preserve | 1773-1781 | 1773-1781 | T91 | patients | PatientOrDisabledGroup | 1,773 | 1,781 | A21 | Because expression and function of CD44v7 in patients with systemic autoimmune disease and IBD have been much like the ones in mice suffering of TNBS-induced colitis, it is tempting to speculate that blockade of CD44v7 could also be of therapeutic relevance in the human diseases. | 1728-2026 | 1,728 | 2,026 | Because expression and function of CD44v7 in @OBJECT$ @PREDICAT$ @SUBJECT$ and IBD have been much like the ones in mice suffering of TNBS-induced colitis, it is tempting to speculate that blockade of CD44v7 could also be of therapeutic relevance in the human diseases. |
Fact | preserve | 2339-2353 | 2344-2353 | T138 | drug treatment | USES | 2,339 | 2,353 | preserve | 2344-2353 | 2344-2353 | T136 | treatment | TherapeuticOrPreventiveProcedure | 2,344 | 2,353 | preserve | 2339-2343 | 2339-2343 | T135 | drug | PharmacologicSubstance | 2,339 | 2,343 | A1 | Even though more subjects in the drug treatment group required reductions in diabetes medications, at 6 months, changes in HbA1c were -0.3 +/- 0.2% with placebo treatment and -1.6 +/- 0.3% with drug treatment (P = 0.002). | 2126-2366 | 2,126 | 2,366 | Even though more subjects in the drug treatment group required reductions in diabetes medications, at 6 months, changes in HbA1c were -0.3 +/- 0.2% with placebo treatment and -1.6 +/- 0.3% with @OBJECT$ @PREDICAT$ @SUBJECT$ (P = 0.002). |
Fact | preserve | 2098-2112 | 2103-2112 | T124 | drug treatment | USES | 2,098 | 2,112 | preserve | 2103-2112 | 2103-2112 | T122 | treatment | TherapeuticOrPreventiveProcedure | 2,103 | 2,112 | preserve | 2098-2102 | 2098-2102 | T121 | drug | PharmacologicSubstance | 2,098 | 2,102 | A2 | Changes in weight at 6 months were -2.7 +/- 1.4 kg (mean +/- SEM) with placebo treatment and -9.6 +/- 1.5 kg with drug treatment (P = 0.003). | 1978-2125 | 1,978 | 2,125 | Changes in weight at 6 months were -2.7 +/- 1.4 kg (mean +/- SEM) with placebo treatment and -9.6 +/- 1.5 kg with @OBJECT$ @PREDICAT$ @SUBJECT$ (P = 0.003). |
Fact | preserve | 1485-1499 | 1490-1499 | T89 | drug treatment | USES | 1,485 | 1,499 | preserve | 1490-1499 | 1490-1499 | T84 | treatment | TherapeuticOrPreventiveProcedure | 1,490 | 1,499 | preserve | 1485-1489 | 1485-1489 | T83 | drug | PharmacologicSubstance | 1,485 | 1,489 | A3 | Thus the length of drug treatment varied, but 16 subjects (8 in each group) reached 12 months of treatment. | 1460-1579 | 1,460 | 1,579 | Thus the length of @OBJECT$ @PREDICAT$ @SUBJECT$ varied, but 16 subjects (8 in each group) reached 12 months of treatment. |
Probable | preserve | 2738-2747 | 2738-2747 | T163 | treatment | TREATS | 2,738 | 2,747 | preserve | 2702-2713 | 2702-2713 | T157 | medications | PharmacologicSubstance | 2,702 | 2,713 | preserve | 2752-2767 | 2759-2767 | T160 | type 2 diabetes | DiseaseOrSyndrome | 2,752 | 2,767 | A5 | However, our data suggest that weight loss medications are an effective treatment for type 2 diabetes during active weight loss. | 2659-2794 | 2,659 | 2,794 | However, our data suggest that weight loss @SUBJECT$ are an effective @PREDICAT$ for @OBJECT$ during active weight loss. |
Fact | preserve | 436-440 | 436-440 | T28 | with | PROCESS_OF | 436 | 440 | preserve | 441-456 | 448-456 | T25 | type 2 diabetes | DiseaseOrSyndrome | 441 | 456 | preserve | 427-435 | 427-435 | T24 | patients | PatientOrDisabledGroup | 427 | 435 | A6 | Pharmacologic agents to assist weight loss might be useful, but no long-term data on their effectiveness and safety in patients with type 2 diabetes are available. | 296-471 | 296 | 471 | Pharmacologic agents to assist weight loss might be useful, but no long-term data on their effectiveness and safety in @OBJECT$ @PREDICAT$ @SUBJECT$ are available. |
Fact | preserve | 1910-1912 | 1910-1912 | T114 | in | TREATS | 1,910 | 1,912 | preserve | 1859-1868 | 1859-1868 | T106 | treatment | TherapeuticOrPreventiveProcedure | 1,859 | 1,868 | preserve | 1913-1924 | 1918-1924 | T108 | body weight | OrganismAttribute | 1,913 | 1,924 | A7 | Drug treatment resulted in significant reductions in body weight, BMI, and HbA1c at all time points through 6 months. | 1854-1977 | 1,854 | 1,977 | Drug @SUBJECT$ resulted in significant reductions @PREDICAT$ @OBJECT$ , BMI, and HbA1c at all time points through 6 months. |
Uncommitted | preserve | 601-603 | 601-603 | T41 | in | TREATS | 601 | 603 | preserve | 572-584 | 572-584 | T35 | fenfluramine | OrganicChemical | 572 | 584 | preserve | 611-619 | 611-619 | T38 | diabetic | Finding | 611 | 619 | A8 | We therefore initiated a 2-year placebo-controlled trial of the weight-loss medications fenfluramine and phentermine in type 2 diabetic subjects. | 472-629 | 472 | 629 | We therefore initiated a 2-year placebo-controlled trial of the weight-loss medications @SUBJECT$ and phentermine @PREDICAT$ type 2 @OBJECT$ subjects. |
Uncommitted | preserve | 601-603 | 601-603 | T41 | in | TREATS | 601 | 603 | preserve | 589-600 | 589-600 | T36 | phentermine | OrganicChemical | 589 | 600 | preserve | 611-619 | 611-619 | T38 | diabetic | Finding | 611 | 619 | A9 | We therefore initiated a 2-year placebo-controlled trial of the weight-loss medications fenfluramine and phentermine in type 2 diabetic subjects. | 472-629 | 472 | 629 | We therefore initiated a 2-year placebo-controlled trial of the weight-loss medications fenfluramine and @SUBJECT$ @PREDICAT$ type 2 @OBJECT$ subjects. |
Fact | preserve | 93-97 | 93-97 | T11 | with | PROCESS_OF | 93 | 97 | preserve | 98-113 | 105-113 | T7 | type 2 diabetes | DiseaseOrSyndrome | 98 | 113 | preserve | 81-92 | 81-92 | T6 | individuals | Human | 81 | 92 | A10 | OBJECTIVE: Most individuals with type 2 diabetes are overweight, and weight loss for them is an important therapeutic objective. | 65-200 | 65 | 200 | OBJECTIVE: Most @OBJECT$ @PREDICAT$ @SUBJECT$ are overweight, and weight loss for them is an important therapeutic objective. |
Fact | preserve | 2049-2072 | 2063-2072 | T123 | placebo treatment | USES | 2,049 | 2,072 | preserve | 2063-2072 | 2063-2072 | T120 | treatment | TherapeuticOrPreventiveProcedure | 2,063 | 2,072 | preserve | 2049-2056 | 2049-2056 | T119 | placebo | MedicalDevice | 2,049 | 2,056 | A11 | Changes in weight at 6 months were -2.7 +/- 1.4 kg (mean +/- SEM) with placebo treatment and -9.6 +/- 1.5 kg with drug treatment (P = 0.003). | 1978-2125 | 1,978 | 2,125 | Changes in weight at 6 months were -2.7 +/- 1.4 kg (mean +/- SEM) with @OBJECT$ @PREDICAT$ @SUBJECT$ and -9.6 +/- 1.5 kg with drug treatment (P = 0.003). |
Fact | preserve | 2291-2308 | 2299-2308 | T137 | placebo treatment | USES | 2,291 | 2,308 | preserve | 2299-2308 | 2299-2308 | T134 | treatment | TherapeuticOrPreventiveProcedure | 2,299 | 2,308 | preserve | 2291-2298 | 2291-2298 | T133 | placebo | MedicalDevice | 2,291 | 2,298 | A12 | Even though more subjects in the drug treatment group required reductions in diabetes medications, at 6 months, changes in HbA1c were -0.3 +/- 0.2% with placebo treatment and -1.6 +/- 0.3% with drug treatment (P = 0.002). | 2126-2366 | 2,126 | 2,366 | Even though more subjects in the drug treatment group required reductions in diabetes medications, at 6 months, changes in HbA1c were -0.3 +/- 0.2% with @OBJECT$ @PREDICAT$ @SUBJECT$ and -1.6 +/- 0.3% with drug treatment (P = 0.002). |
Fact | preserve | 42-47 | 42-47 | T5 | treat | TREATS | 42 | 47 | preserve | 14-23 | 14-23 | T2 | induction | TherapeuticOrPreventiveProcedure | 14 | 23 | preserve | 48-63 | 55-63 | T4 | type 2 diabetes | DiseaseOrSyndrome | 48 | 63 | A13 | Pharmacologic induction of weight loss to treat type 2 diabetes. | 0-64 | 0 | 64 | Pharmacologic @SUBJECT$ of weight loss to @PREDICAT$ @OBJECT$ . |
Fact | preserve | 1854-1868 | 1859-1868 | T113 | Drug treatment | USES | 1,854 | 1,868 | preserve | 1859-1868 | 1859-1868 | T106 | treatment | TherapeuticOrPreventiveProcedure | 1,859 | 1,868 | preserve | 1854-1858 | 1854-1858 | T105 | Drug | PharmacologicSubstance | 1,854 | 1,858 | A15 | Drug treatment resulted in significant reductions in body weight, BMI, and HbA1c at all time points through 6 months. | 1854-1977 | 1,854 | 1,977 | @OBJECT$ @PREDICAT$ @SUBJECT$ resulted in significant reductions in body weight, BMI, and HbA1c at all time points through 6 months. |
Fact | preserve | 560-584 | 572-584 | T40 | medications fenfluramine | ISA | 560 | 584 | preserve | 572-584 | 572-584 | T35 | fenfluramine | OrganicChemical | 572 | 584 | preserve | 560-571 | 560-571 | T34 | medications | PharmacologicSubstance | 560 | 571 | A16 | We therefore initiated a 2-year placebo-controlled trial of the weight-loss medications fenfluramine and phentermine in type 2 diabetic subjects. | 472-629 | 472 | 629 | We therefore initiated a 2-year placebo-controlled trial of the weight-loss @OBJECT$ @PREDICAT$ @SUBJECT$ and phentermine in type 2 diabetic subjects. |
Fact | preserve | 2466-2480 | 2471-2480 | T146 | drug treatment | USES | 2,466 | 2,480 | preserve | 2471-2480 | 2471-2480 | T145 | treatment | TherapeuticOrPreventiveProcedure | 2,471 | 2,480 | preserve | 2466-2470 | 2466-2470 | T144 | drug | PharmacologicSubstance | 2,466 | 2,470 | A17 | Fasting plasma glucose and triglycerides were significantly reduced at some time points with drug treatment. | 2367-2481 | 2,367 | 2,481 | Fasting plasma glucose and triglycerides were significantly reduced at some time points with @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1721-1730 | 1721-1730 | T98 | prevented | PREVENTS | 1,721 | 1,730 | preserve | 1701-1710 | 1701-1710 | T85 | captopril | AminoAcidPeptideOrProtein | 1,701 | 1,710 | preserve | 1748-1756 | 1748-1756 | T87 | diabetes | DiseaseOrSyndrome | 1,748 | 1,756 | A1 | These data may explain why, in the CAPP trial, captopril which has prevented more effectively diabetes occurrence could not be proved superior to diuretics and/or betablocker in the prevention of myocardial infarction and specially of strokes for which exist on the contrary a suspicion of a lower protection. | 1648-1982 | 1,648 | 1,982 | These data may explain why, in the CAPP trial, @SUBJECT$ which has @PREDICAT$ more effectively @OBJECT$ occurrence could not be proved superior to diuretics and/or betablocker in the prevention of myocardial infarction and specially of strokes for which exist on the contrary a suspicion of a lower protection. |
Fact | preserve | 1842-1852 | 1842-1852 | T99 | prevention | PREVENTS | 1,842 | 1,852 | preserve | 1806-1815 | 1806-1815 | T91 | diuretics | PharmacologicSubstance | 1,806 | 1,815 | preserve | 1862-1883 | 1873-1883 | T93 | myocardial infarction | DiseaseOrSyndrome | 1,862 | 1,883 | A2 | These data may explain why, in the CAPP trial, captopril which has prevented more effectively diabetes occurrence could not be proved superior to diuretics and/or betablocker in the prevention of myocardial infarction and specially of strokes for which exist on the contrary a suspicion of a lower protection. | 1648-1982 | 1,648 | 1,982 | These data may explain why, in the CAPP trial, captopril which has prevented more effectively diabetes occurrence could not be proved superior to @SUBJECT$ and/or betablocker in the @PREDICAT$ of @OBJECT$ and specially of strokes for which exist on the contrary a suspicion of a lower protection. |
Fact | preserve | 1230-1234 | 1230-1234 | T69 | than | higher_than | 1,230 | 1,234 | preserve | 1213-1218 | 1213-1218 | T57 | AT1RA | AminoAcidPeptideOrProtein | 1,213 | 1,218 | preserve | 1235-1239 | 1235-1239 | T60 | ACEI | PharmacologicSubstance | 1,235 | 1,239 | A3 | Despite of their common suppressive effect on angiogenesis AT1RA may better than ACEI protect against ischemic events specially the cerebral ones because they favor the rapid recruitment of collateral circulation. | 1148-1379 | 1,148 | 1,379 | Despite of their common suppressive effect on angiogenesis @SUBJECT$ may better @PREDICAT$ @OBJECT$ protect against ischemic events specially the cerebral ones because they favor the rapid recruitment of collateral circulation. |
Fact | preserve | 1621-1630 | 1621-1630 | T82 | abolishes | INHIBITS | 1,621 | 1,630 | preserve | 1611-1620 | 1611-1620 | T78 | enalapril | AminoAcidPeptideOrProtein | 1,611 | 1,620 | preserve | 1636-1646 | 1636-1646 | T79 | protection | Finding | 1,636 | 1,646 | A4 | This has been demonstrated for losartan in case of abrupt ligation of the carotid in the gerbil since its previous administration protects against fatal cerebral ischemia whereas its previous administration with enalapril abolishes this protection. | 1380-1647 | 1,380 | 1,647 | This has been demonstrated for losartan in case of abrupt ligation of the carotid in the gerbil since its previous administration protects against fatal cerebral ischemia whereas its previous administration with @SUBJECT$ @PREDICAT$ this @OBJECT$ . |
Fact | preserve | 1516-1524 | 1516-1524 | T81 | protects | PREVENTS | 1,516 | 1,524 | preserve | 1411-1419 | 1411-1419 | T70 | losartan | OrganicChemical | 1,411 | 1,419 | preserve | 1546-1563 | 1555-1563 | T76 | cerebral ischemia | DiseaseOrSyndrome | 1,546 | 1,563 | A5 | This has been demonstrated for losartan in case of abrupt ligation of the carotid in the gerbil since its previous administration protects against fatal cerebral ischemia whereas its previous administration with enalapril abolishes this protection. | 1380-1647 | 1,380 | 1,647 | This has been demonstrated for @SUBJECT$ in case of abrupt ligation of the carotid in the gerbil since its previous administration @PREDICAT$ against fatal @OBJECT$ whereas its previous administration with enalapril abolishes this protection. |
Fact | preserve | 947-955 | 947-955 | T52 | decrease | INHIBITS | 947 | 955 | preserve | 926-930 | 926-930 | T39 | ACEI | PharmacologicSubstance | 926 | 930 | preserve | 956-968 | 956-968 | T43 | angiogenesis | OrganOrTissueFunction | 956 | 968 | A6 | Experimentally ACEI and AT1RA decrease angiogenesis and cellular proliferation and favor cellular differentiation which could explain the protective effect of ACEI against cancer suggested recently in a Scotish study. | 911-1147 | 911 | 1,147 | Experimentally @SUBJECT$ and AT1RA @PREDICAT$ @OBJECT$ and cellular proliferation and favor cellular differentiation which could explain the protective effect of ACEI against cancer suggested recently in a Scotish study. |
Fact | preserve | 756-767 | 756-767 | T38 | stimulation | STIMULATES | 756 | 767 | preserve | 657-660 | 657-660 | T28 | AT1 | GeneOrGenome | 657 | 660 | preserve | 777-780 | 777-780 | T33 | AT2 | AminoAcidPeptideOrProtein | 777 | 780 | A7 | Angiotensin converting enzyme inhibitors (ACEI) decrease the synthesis of All and therefore the stimulation of both receptor types whereas AT1-receptor antagonists (AT1RA) block only the stimulation of these latter and increase the stimulation of AT2 receptor since they increase the production of All secondarily to the inhibition of the feedback of renin secretion by All. | 512-910 | 512 | 910 | Angiotensin converting enzyme inhibitors (ACEI) decrease the synthesis of All and therefore the stimulation of both receptor types whereas @SUBJECT$ -receptor antagonists (AT1RA) block only the stimulation of these latter and increase the @PREDICAT$ of @OBJECT$ receptor since they increase the production of All secondarily to the inhibition of the feedback of renin secretion by All. |
Fact | preserve | 1230-1234 | 1230-1234 | T68 | than | compared_with | 1,230 | 1,234 | preserve | 1213-1218 | 1213-1218 | T57 | AT1RA | AminoAcidPeptideOrProtein | 1,213 | 1,218 | preserve | 1235-1239 | 1235-1239 | T60 | ACEI | PharmacologicSubstance | 1,235 | 1,239 | A8 | Despite of their common suppressive effect on angiogenesis AT1RA may better than ACEI protect against ischemic events specially the cerebral ones because they favor the rapid recruitment of collateral circulation. | 1148-1379 | 1,148 | 1,379 | Despite of their common suppressive effect on angiogenesis @SUBJECT$ may better @PREDICAT$ @OBJECT$ protect against ischemic events specially the cerebral ones because they favor the rapid recruitment of collateral circulation. |
Fact | preserve | 794-796 | 794-796 | T57 | in | LOCATION_OF | 794 | 796 | preserve | 808-816 | 808-816 | T55 | patients | PatientOrDisabledGroup | 808 | 816 | preserve | 748-761 | 748-761 | T53 | triglycerides | BiologicallyActiveSubstance | 748 | 761 | A3 | Furthermore, a positive correlation between the level of F VIIC and triglycerides (TG) or total cholesterol (TCh) in the patients and sons was revealed. | 673-839 | 673 | 839 | Furthermore, a positive correlation between the level of F VIIC and @OBJECT$ (TG) or total cholesterol (TCh) @PREDICAT$ the @SUBJECT$ and sons was revealed. |
Fact | preserve | 794-796 | 794-796 | T57 | in | LOCATION_OF | 794 | 796 | preserve | 821-825 | 821-825 | T56 | sons | FamilyGroup | 821 | 825 | preserve | 770-787 | 776-787 | T54 | total cholesterol | Steroid | 770 | 787 | A5 | Furthermore, a positive correlation between the level of F VIIC and triglycerides (TG) or total cholesterol (TCh) in the patients and sons was revealed. | 673-839 | 673 | 839 | Furthermore, a positive correlation between the level of F VIIC and triglycerides (TG) or @OBJECT$ (TCh) @PREDICAT$ the patients and @SUBJECT$ was revealed. |
Uncommitted | preserve | 259-261 | 259-261 | T31 | in | TREATS | 259 | 261 | preserve | 228-244 | 228-240 | T19 | antithrombin III | AminoAcidPeptideOrProtein | 228 | 244 | preserve | 262-265 | 262-265 | T20 | men | PopulationGroup | 262 | 265 | A6 | The concentrations of fibrinogen (Fb) and the activities of factor VII (F VIIC) and antithrombin III (AT III) both in men less than 55 years old with a history of myocardial infarction (MI) and with normolipemia (MI-NLP) or hyperlipoproteinemia (MI-HLP) and in their sons have been measured. | 138-447 | 138 | 447 | The concentrations of fibrinogen (Fb) and the activities of factor VII (F VIIC) and @SUBJECT$ (AT III) both @PREDICAT$ @OBJECT$ less than 55 years old with a history of myocardial infarction (MI) and with normolipemia (MI-NLP) or hyperlipoproteinemia (MI-HLP) and in their sons have been measured. |
Fact | preserve | 954-956 | 954-956 | T78 | in | LOCATION_OF | 954 | 956 | preserve | 964-972 | 964-972 | T71 | patients | PatientOrDisabledGroup | 964 | 972 | preserve | 944-946 | 944-946 | T67 | TG | BiologicallyActiveSubstance | 944 | 946 | A7 | A positive correlation was found between: (a) Fb levels in MI-HLP patients and in their sons; (b) TG levels in MI-HLP patients and in their sons; and (c) AT III activity in MI patients and in their sons. | 840-1056 | 840 | 1,056 | A positive correlation was found between: (a) Fb levels in MI-HLP patients and in their sons; (b) @OBJECT$ levels @PREDICAT$ MI-HLP @SUBJECT$ and in their sons; and (c) AT III activity in MI patients and in their sons. |
Fact | preserve | 794-796 | 794-796 | T57 | in | LOCATION_OF | 794 | 796 | preserve | 808-816 | 808-816 | T55 | patients | PatientOrDisabledGroup | 808 | 816 | preserve | 770-787 | 776-787 | T54 | total cholesterol | Steroid | 770 | 787 | A9 | Furthermore, a positive correlation between the level of F VIIC and triglycerides (TG) or total cholesterol (TCh) in the patients and sons was revealed. | 673-839 | 673 | 839 | Furthermore, a positive correlation between the level of F VIIC and triglycerides (TG) or @OBJECT$ (TCh) @PREDICAT$ the @SUBJECT$ and sons was revealed. |
Counterfact | preserve | 664-666 | 664-666 | T49 | in | PROCESS_OF | 664 | 666 | preserve | 631-652 | 643-652 | T47 | haemostatic disorders | DiseaseOrSyndrome | 631 | 652 | preserve | 667-671 | 667-671 | T48 | sons | FamilyGroup | 667 | 671 | A10 | No lipid or haemostatic disorders were noted in sons. | 612-672 | 612 | 672 | No lipid or @SUBJECT$ were noted @PREDICAT$ @OBJECT$ . |
Fact | preserve | 92-96 | 92-96 | T12 | with | PROCESS_OF | 92 | 96 | preserve | 97-118 | 108-118 | T9 | myocardial infarction | DiseaseOrSyndrome | 97 | 118 | preserve | 88-91 | 88-91 | T8 | men | PopulationGroup | 88 | 91 | A11 | Fibrinogen, factor VII, antithrombin III, cholesterol and triglycerides in young men with myocardial infarction and in their sons. | 0-137 | 0 | 137 | Fibrinogen, factor VII, antithrombin III, cholesterol and triglycerides in young @OBJECT$ @PREDICAT$ @SUBJECT$ and in their sons. |
Fact | preserve | 1324-1326 | 1324-1326 | T101 | in | ASSOCIATED_WITH | 1,324 | 1,326 | preserve | 1247-1253 | 1250-1253 | T94 | AT III | AminoAcidPeptideOrProtein | 1,247 | 1,253 | preserve | 1327-1330 | 1327-1330 | T98 | IHD | DiseaseOrSyndrome | 1,327 | 1,330 | A12 | Elevated activities of AT III may reflect the haemostatic response to the prothrombotic state in IHD on the one hand whereas they may contribute to the development of IHD on the other. | 1217-1420 | 1,217 | 1,420 | Elevated activities of @SUBJECT$ may reflect the haemostatic response to the prothrombotic state @PREDICAT$ @OBJECT$ on the one hand whereas they may contribute to the development of IHD on the other. |
Fact | preserve | 984-986 | 984-986 | T79 | in | LOCATION_OF | 984 | 986 | preserve | 993-997 | 993-997 | T72 | sons | FamilyGroup | 993 | 997 | preserve | 944-946 | 944-946 | T67 | TG | BiologicallyActiveSubstance | 944 | 946 | A13 | A positive correlation was found between: (a) Fb levels in MI-HLP patients and in their sons; (b) TG levels in MI-HLP patients and in their sons; and (c) AT III activity in MI patients and in their sons. | 840-1056 | 840 | 1,056 | A positive correlation was found between: (a) Fb levels in MI-HLP patients and in their sons; (b) @OBJECT$ levels in MI-HLP patients and @PREDICAT$ their @SUBJECT$ ; and (c) AT III activity in MI patients and in their sons. |
Uncommitted | preserve | 72-74 | 72-74 | T11 | in | TREATS | 72 | 74 | preserve | 24-40 | 24-36 | T4 | antithrombin III | AminoAcidPeptideOrProtein | 24 | 40 | preserve | 88-91 | 88-91 | T8 | men | PopulationGroup | 88 | 91 | A14 | Fibrinogen, factor VII, antithrombin III, cholesterol and triglycerides in young men with myocardial infarction and in their sons. | 0-137 | 0 | 137 | Fibrinogen, factor VII, @SUBJECT$ , cholesterol and triglycerides @PREDICAT$ young @OBJECT$ with myocardial infarction and in their sons. |
Uncommitted | preserve | 72-74 | 72-74 | T11 | in | TREATS | 72 | 74 | preserve | 24-40 | 24-36 | T4 | antithrombin III | AminoAcidPeptideOrProtein | 24 | 40 | preserve | 97-118 | 108-118 | T9 | myocardial infarction | DiseaseOrSyndrome | 97 | 118 | A16 | Fibrinogen, factor VII, antithrombin III, cholesterol and triglycerides in young men with myocardial infarction and in their sons. | 0-137 | 0 | 137 | Fibrinogen, factor VII, @SUBJECT$ , cholesterol and triglycerides @PREDICAT$ young men with @OBJECT$ and in their sons. |
Fact | preserve | 794-796 | 794-796 | T57 | in | LOCATION_OF | 794 | 796 | preserve | 821-825 | 821-825 | T56 | sons | FamilyGroup | 821 | 825 | preserve | 748-761 | 748-761 | T53 | triglycerides | BiologicallyActiveSubstance | 748 | 761 | A17 | Furthermore, a positive correlation between the level of F VIIC and triglycerides (TG) or total cholesterol (TCh) in the patients and sons was revealed. | 673-839 | 673 | 839 | Furthermore, a positive correlation between the level of F VIIC and @OBJECT$ (TG) or total cholesterol (TCh) @PREDICAT$ the patients and @SUBJECT$ was revealed. |
Fact | preserve | 414-416 | 414-416 | T32 | in | PROCESS_OF | 414 | 416 | preserve | 380-400 | 380-400 | T27 | hyperlipoproteinemia | DiseaseOrSyndrome | 380 | 400 | preserve | 423-427 | 423-427 | T30 | sons | FamilyGroup | 423 | 427 | A18 | The concentrations of fibrinogen (Fb) and the activities of factor VII (F VIIC) and antithrombin III (AT III) both in men less than 55 years old with a history of myocardial infarction (MI) and with normolipemia (MI-NLP) or hyperlipoproteinemia (MI-HLP) and in their sons have been measured. | 138-447 | 138 | 447 | The concentrations of fibrinogen (Fb) and the activities of factor VII (F VIIC) and antithrombin III (AT III) both in men less than 55 years old with a history of myocardial infarction (MI) and with normolipemia (MI-NLP) or @SUBJECT$ (MI-HLP) and @PREDICAT$ their @OBJECT$ have been measured. |
Possible | preserve | 1082-1092 | 1082-1092 | T91 | associated | ASSOCIATED_WITH | 1,082 | 1,092 | preserve | 1057-1067 | 1057-1067 | T86 | Fibrinogen | AminoAcidPeptideOrProtein | 1,057 | 1,067 | preserve | 1098-1120 | 1113-1120 | T87 | ischemic heart disease | DiseaseOrSyndrome | 1,098 | 1,120 | A19 | Fibrinogen appears to be associated with ischemic heart disease more closely than factor VII, the latter being strongly linked with hypertriglyceridemia. | 1057-1216 | 1,057 | 1,216 | @SUBJECT$ appears to be @PREDICAT$ with @OBJECT$ more closely than factor VII, the latter being strongly linked with hypertriglyceridemia. |
Fact | preserve | 1026-1037 | 1029-1037 | T83 | MI patients | PROCESS_OF | 1,026 | 1,037 | preserve | 1026-1028 | 1026-1028 | T75 | MI | DiseaseOrSyndrome | 1,026 | 1,028 | preserve | 1029-1037 | 1029-1037 | T76 | patients | PatientOrDisabledGroup | 1,029 | 1,037 | A20 | A positive correlation was found between: (a) Fb levels in MI-HLP patients and in their sons; (b) TG levels in MI-HLP patients and in their sons; and (c) AT III activity in MI patients and in their sons. | 840-1056 | 840 | 1,056 | A positive correlation was found between: (a) Fb levels in MI-HLP patients and in their sons; (b) TG levels in MI-HLP patients and in their sons; and (c) AT III activity in @SUBJECT$ @PREDICAT$ @OBJECT$ and in their sons. |
Fact | preserve | 1136-1175 | 1168-1175 | T73 | plasma atrial natriuretic peptide | LOCATION_OF | 1,136 | 1,175 | preserve | 1136-1142 | 1136-1142 | T67 | plasma | BodySubstance | 1,136 | 1,142 | preserve | 1143-1175 | 1168-1175 | T68 | atrial natriuretic peptide | AminoAcidPeptideOrProtein | 1,143 | 1,175 | A1 | The presence of heart failure was indicated by increased lung weights, left ventricular end-diastolic pressure and systemic vascular resistance, reduced cardiac output and increased levels of plasma atrial natriuretic peptide (166%), adrenaline (x20), noradrenaline (106%) and dopamine (x3). | 932-1247 | 932 | 1,247 | The presence of heart failure was indicated by increased lung weights, left ventricular end-diastolic pressure and systemic vascular resistance, reduced cardiac output and increased levels of @SUBJECT$ @PREDICAT$ @OBJECT$ (166%), adrenaline (x20), noradrenaline (106%) and dopamine (x3). |
Fact | preserve | 936-944 | 936-944 | T72 | presence | COEXISTS_WITH | 936 | 944 | preserve | 1097-1111 | 1105-1111 | T64 | cardiac output | Finding | 1,097 | 1,111 | preserve | 948-961 | 954-961 | T57 | heart failure | DiseaseOrSyndrome | 948 | 961 | A2 | The presence of heart failure was indicated by increased lung weights, left ventricular end-diastolic pressure and systemic vascular resistance, reduced cardiac output and increased levels of plasma atrial natriuretic peptide (166%), adrenaline (x20), noradrenaline (106%) and dopamine (x3). | 932-1247 | 932 | 1,247 | The @PREDICAT$ of @OBJECT$ was indicated by increased lung weights, left ventricular end-diastolic pressure and systemic vascular resistance, reduced @SUBJECT$ and increased levels of plasma atrial natriuretic peptide (166%), adrenaline (x20), noradrenaline (106%) and dopamine (x3). |
Fact | preserve | 2105-2109 | 2105-2109 | T119 | with | PROCESS_OF | 2,105 | 2,109 | preserve | 2110-2152 | 2141-2152 | T117 | left ventricular outflow obstruction | DiseaseOrSyndrome | 2,110 | 2,152 | preserve | 2096-2104 | 2096-2104 | T116 | patients | PatientOrDisabledGroup | 2,096 | 2,104 | A3 | We hypothesize that increased endothelium-mediated vasodilatation may contribute to hypotension and syncope in patients with left ventricular outflow obstruction. | 1978-2153 | 1,978 | 2,153 | We hypothesize that increased endothelium-mediated vasodilatation may contribute to hypotension and syncope in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1810-1818 | 1810-1818 | T109 | resulted | CAUSES | 1,810 | 1,818 | preserve | 1768-1780 | 1768-1780 | T98 | constriction | TherapeuticOrPreventiveProcedure | 1,768 | 1,780 | preserve | 1822-1835 | 1828-1835 | T100 | heart failure | DiseaseOrSyndrome | 1,822 | 1,835 | A5 | Chronic constriction of the ascending aorta resulted in heart failure and increased vasodilator responses to acetylcholine and isoprenaline in the distal aorta while dynamic compliance was unchanged. | 1760-1977 | 1,760 | 1,977 | Chronic @SUBJECT$ of the ascending aorta @PREDICAT$ in @OBJECT$ and increased vasodilator responses to acetylcholine and isoprenaline in the distal aorta while dynamic compliance was unchanged. |
Fact | preserve | 96-102 | 96-99 | T10 | due to | CAUSES | 96 | 102 | preserve | 112-127 | 119-127 | T7 | aortic stenosis | DiseaseOrSyndrome | 112 | 127 | preserve | 76-95 | 88-95 | T5 | heart failure | DiseaseOrSyndrome | 76 | 95 | A6 | Investigation of distal aortic compliance and vasodilator responsiveness in heart failure due to proximal aortic stenosis in the guinea pig. | 0-146 | 0 | 146 | Investigation of distal aortic compliance and vasodilator responsiveness in @OBJECT$ @PREDICAT$ proximal @SUBJECT$ in the guinea pig. |
Fact | preserve | 2093-2095 | 2093-2095 | T118 | in | PROCESS_OF | 2,093 | 2,095 | preserve | 2085-2092 | 2085-2092 | T115 | syncope | SignOrSymptom | 2,085 | 2,092 | preserve | 2096-2104 | 2096-2104 | T116 | patients | PatientOrDisabledGroup | 2,096 | 2,104 | A7 | We hypothesize that increased endothelium-mediated vasodilatation may contribute to hypotension and syncope in patients with left ventricular outflow obstruction. | 1978-2153 | 1,978 | 2,153 | We hypothesize that increased endothelium-mediated vasodilatation may contribute to hypotension and @SUBJECT$ @PREDICAT$ @OBJECT$ with left ventricular outflow obstruction. |
Uncommitted | preserve | 293-295 | 293-295 | T25 | in | ASSOCIATED_WITH | 293 | 295 | preserve | 260-269 | 260-269 | T18 | responses | ClinicalAttribute | 260 | 269 | preserve | 305-327 | 321-327 | T21 | abdominal aortae | BodyPartOrganOrOrganComponent | 305 | 327 | A9 | This study examined vasomotor responses and dynamic compliance in isolated abdominal aortae after chronic constriction of the ascending aorta. | 223-378 | 223 | 378 | This study examined vasomotor @SUBJECT$ and dynamic compliance @PREDICAT$ isolated @OBJECT$ after chronic constriction of the ascending aorta. |
Fact | preserve | 128-130 | 128-130 | T11 | in | PROCESS_OF | 128 | 130 | preserve | 112-127 | 119-127 | T7 | aortic stenosis | DiseaseOrSyndrome | 112 | 127 | preserve | 135-145 | 142-145 | T8 | guinea pig | Mammal | 135 | 145 | A10 | Investigation of distal aortic compliance and vasodilator responsiveness in heart failure due to proximal aortic stenosis in the guinea pig. | 0-146 | 0 | 146 | Investigation of distal aortic compliance and vasodilator responsiveness in heart failure due to proximal @SUBJECT$ @PREDICAT$ the @OBJECT$ . |
Fact | preserve | 1347-1367 | 1361-1367 | T71 | breast tumour growth | PART_OF | 1,347 | 1,367 | preserve | 1354-1367 | 1361-1367 | T68 | tumour growth | NeoplasticProcess | 1,354 | 1,367 | preserve | 1347-1353 | 1347-1353 | T67 | breast | BodyPartOrganOrOrganComponent | 1,347 | 1,353 | A1 | There is also evidence suggesting that the agonist activity of this compound may ultimately stimulate breast tumour growth, thus causing some treatment failures. | 1239-1412 | 1,239 | 1,412 | There is also evidence suggesting that the agonist activity of this compound may ultimately stimulate @OBJECT$ @PREDICAT$ @SUBJECT$ , thus causing some treatment failures. |
Fact | preserve | 1502-1504 | 1502-1504 | T78 | in | PROCESS_OF | 1,502 | 1,504 | preserve | 1486-1501 | 1486-1501 | T76 | drug-resistance | BiologicFunction | 1,486 | 1,501 | preserve | 1510-1518 | 1510-1518 | T77 | patients | PatientOrDisabledGroup | 1,510 | 1,518 | A2 | Moreover, the use of tamoxifen is limited by the possible onset of drug-resistance in many patients. | 1413-1519 | 1,413 | 1,519 | Moreover, the use of tamoxifen is limited by the possible onset of @SUBJECT$ @PREDICAT$ many @OBJECT$ . |
Fact | preserve | 707-715 | 707-715 | T34 | blockade | INHIBITS | 707 | 715 | preserve | 736-751 | 736-751 | T32 | antioestrogenic | PharmacologicSubstance | 736 | 751 | preserve | 689-706 | 698-706 | T31 | hormonal receptor | AminoAcidPeptideOrProtein | 689 | 706 | A3 | The surgical removal of steroid-secreting glands, in order to reduce the level of oestrogens reaching their target tissues, has for years been substituted by the so-called endocrinotherapeutic approach, which is based on the counteraction of the steroid hormone activity by the hormonal receptor blockade with suitable antioestrogenic compounds. | 392-762 | 392 | 762 | The surgical removal of steroid-secreting glands, in order to reduce the level of oestrogens reaching their target tissues, has for years been substituted by the so-called endocrinotherapeutic approach, which is based on the counteraction of the steroid hormone activity by the @OBJECT$ @PREDICAT$ with suitable @SUBJECT$ compounds. |
Fact | preserve | 984-991 | 984-991 | T52 | binding | INTERACTS_WITH | 984 | 991 | preserve | 915-932 | 915-932 | T45 | triphenylethylene | OrganicChemical | 915 | 932 | preserve | 999-1017 | 1009-1017 | T48 | oestrogen receptor | AminoAcidPeptideOrProtein | 999 | 1,017 | A5 | The triphenylethylene-derivative compound competes efficiently for binding to the oestrogen receptor, but the complex retains some transcriptional activity. | 911-1079 | 911 | 1,079 | The @SUBJECT$ -derivative compound competes efficiently for @PREDICAT$ to the @OBJECT$ , but the complex retains some transcriptional activity. |
Fact | preserve | 251-263 | 258-263 | T20 | breast cells | PART_OF | 251 | 263 | preserve | 241-263 | 258-263 | T15 | malignant breast cells | Cell | 241 | 263 | preserve | 251-257 | 251-257 | T14 | breast | BodyPartOrganOrOrganComponent | 251 | 257 | A6 | The rationale underlying therapeutic strategies designed to inhibit the action of endogenous sex hormones in malignant breast cells is provided by the demonstration of their involvement in supporting the development and growth of breast carcinoma. | 126-391 | 126 | 391 | The rationale underlying therapeutic strategies designed to inhibit the action of endogenous sex hormones in @SUBJECT$ @OBJECT$ @PREDICAT$ is provided by the demonstration of their involvement in supporting the development and growth of breast carcinoma. |
Fact | preserve | 44-46 | 44-46 | T9 | in | TREATS | 44 | 46 | preserve | 21-43 | 32-43 | T3 | oestradiol antagonists | PharmacologicSubstance | 21 | 43 | preserve | 47-64 | 55-64 | T4 | mammary carcinoma | NeoplasticProcess | 47 | 64 | A7 | New vs old fashioned oestradiol antagonists in mammary carcinoma: 'in vitro' and 'in vivo' pharmacological approaches. | 0-125 | 0 | 125 | New vs old fashioned @SUBJECT$ @PREDICAT$ @OBJECT$ : 'in vitro' and 'in vivo' pharmacological approaches. |
Fact | preserve | 882-891 | 882-891 | T44 | treatment | TREATS | 882 | 891 | preserve | 832-841 | 832-841 | T39 | tamoxifen | OrganicChemical | 832 | 841 | preserve | 896-909 | 903-909 | T43 | breast cancer | NeoplasticProcess | 896 | 909 | A9 | Over the past 25 years, the non-steroidal oestrogen antagonist tamoxifen has become the standard endocrine treatment for breast cancer. | 763-910 | 763 | 910 | Over the past 25 years, the non-steroidal oestrogen antagonist @SUBJECT$ has become the standard endocrine @PREDICAT$ for @OBJECT$ . |
Fact | preserve | 2065-2067 | 2065-2067 | T129 | in | TREATS | 2,065 | 2,067 | preserve | 1996-2005 | 1996-2005 | T122 | tamoxifen | OrganicChemical | 1,996 | 2,005 | preserve | 2086-2091 | 2086-2091 | T126 | women | PopulationGroup | 2,086 | 2,091 | A1 | Our study, involving a representative sample of physicians practicing in Italy, shows that tamoxifen is not used optimally, with a substantial under-use in younger women and women with node-negative disease. | 1898-2119 | 1,898 | 2,119 | Our study, involving a representative sample of physicians practicing in Italy, shows that @SUBJECT$ is not used optimally, with a substantial under-use @PREDICAT$ younger women and @OBJECT$ with node-negative disease. |
Fact | preserve | 1560-1563 | 1560-1563 | T98 | for | TREATS | 1,560 | 1,563 | preserve | 1536-1545 | 1536-1545 | T94 | tamoxifen | OrganicChemical | 1,536 | 1,545 | preserve | 1573-1581 | 1573-1581 | T97 | patients | PatientOrDisabledGroup | 1,573 | 1,581 | A5 | Older clinicians were less likely to prescribe tamoxifen, particularly for low-risk patients. | 1483-1582 | 1,483 | 1,582 | Older clinicians were less likely to prescribe @SUBJECT$ , particularly @PREDICAT$ low-risk @OBJECT$ . |
Fact | preserve | 1759-1787 | 1779-1787 | T116 | breast cancer patients | PROCESS_OF | 1,759 | 1,787 | preserve | 1759-1772 | 1766-1772 | T106 | breast cancer | NeoplasticProcess | 1,759 | 1,772 | preserve | 1779-1787 | 1779-1787 | T107 | patients | PatientOrDisabledGroup | 1,779 | 1,787 | A6 | CONCLUSIONS: According to the data of the recent EBCTG overview, an additional 20,000 lives could be saved worldwide each year if tamoxifen were given to all early breast cancer patients with hormone-sensitive disease, irrespective of age and disease stage, and for a minimum of five years. | 1583-1897 | 1,583 | 1,897 | CONCLUSIONS: According to the data of the recent EBCTG overview, an additional 20,000 lives could be saved worldwide each year if tamoxifen were given to all early @SUBJECT$ @PREDICAT$ @OBJECT$ with hormone-sensitive disease, irrespective of age and disease stage, and for a minimum of five years. |
Fact | preserve | 712-737 | 731-737 | T45 | woman's menopausal status | PROCESS_OF | 712 | 737 | preserve | 720-737 | 731-737 | T41 | menopausal status | ClinicalAttribute | 720 | 737 | preserve | 712-719 | 712-717 | T40 | woman's | PopulationGroup | 712 | 719 | A7 | MATERIALS AND METHODS: A questionnaire was mailed to a random sample of physicians inquiring as to their preferences with respect to adjuvant tamoxifen, and the usual duration of the treatment applied in various clinical scenarios (according to a woman's menopausal status, the oestrogen receptor status and the stage of disease). | 446-802 | 446 | 802 | MATERIALS AND METHODS: A questionnaire was mailed to a random sample of physicians inquiring as to their preferences with respect to adjuvant tamoxifen, and the usual duration of the treatment applied in various clinical scenarios (according to a @OBJECT$ @PREDICAT$ @SUBJECT$ , the oestrogen receptor status and the stage of disease). |
Fact | preserve | 1788-1792 | 1788-1792 | T117 | with | PROCESS_OF | 1,788 | 1,792 | preserve | 1811-1818 | 1811-1818 | T109 | disease | DiseaseOrSyndrome | 1,811 | 1,818 | preserve | 1779-1787 | 1779-1787 | T107 | patients | PatientOrDisabledGroup | 1,779 | 1,787 | A12 | CONCLUSIONS: According to the data of the recent EBCTG overview, an additional 20,000 lives could be saved worldwide each year if tamoxifen were given to all early breast cancer patients with hormone-sensitive disease, irrespective of age and disease stage, and for a minimum of five years. | 1583-1897 | 1,583 | 1,897 | CONCLUSIONS: According to the data of the recent EBCTG overview, an additional 20,000 lives could be saved worldwide each year if tamoxifen were given to all early breast cancer @OBJECT$ @PREDICAT$ hormone-sensitive @SUBJECT$ , irrespective of age and disease stage, and for a minimum of five years. |
Fact | preserve | 44-53 | 44-53 | T5 | treatment | TREATS | 44 | 53 | preserve | 12-21 | 12-21 | T2 | tamoxifen | OrganicChemical | 12 | 21 | preserve | 57-70 | 64-70 | T4 | breast cancer | NeoplasticProcess | 57 | 70 | A13 | Is adjuvant tamoxifen used optimally in the treatment of breast cancer? | 0-71 | 0 | 71 | Is adjuvant @SUBJECT$ used optimally in the @PREDICAT$ of @OBJECT$ ? |
Fact | preserve | 2065-2067 | 2065-2067 | T129 | in | TREATS | 2,065 | 2,067 | preserve | 1996-2005 | 1996-2005 | T122 | tamoxifen | OrganicChemical | 1,996 | 2,005 | preserve | 2076-2081 | 2076-2081 | T125 | women | PopulationGroup | 2,076 | 2,081 | A14 | Our study, involving a representative sample of physicians practicing in Italy, shows that tamoxifen is not used optimally, with a substantial under-use in younger women and women with node-negative disease. | 1898-2119 | 1,898 | 2,119 | Our study, involving a representative sample of physicians practicing in Italy, shows that @SUBJECT$ is not used optimally, with a substantial under-use @PREDICAT$ younger @OBJECT$ and women with node-negative disease. |
Fact | preserve | 364-386 | 378-386 | T26 | breast cancer patients | PROCESS_OF | 364 | 386 | preserve | 364-377 | 371-377 | T20 | breast cancer | NeoplasticProcess | 364 | 377 | preserve | 378-386 | 378-386 | T21 | patients | PatientOrDisabledGroup | 378 | 386 | A15 | The aim of this study was to determine what physicians know about, and their opinions of, hormone treatment in breast cancer patients, and the factors comprising their medical decision-making. | 241-445 | 241 | 445 | The aim of this study was to determine what physicians know about, and their opinions of, hormone treatment in @SUBJECT$ @PREDICAT$ @OBJECT$ , and the factors comprising their medical decision-making. |
Uncommitted | preserve | 1740-1745 | 1740-1745 | T115 | given | ADMINISTERED_TO | 1,740 | 1,745 | preserve | 1725-1734 | 1725-1734 | T104 | tamoxifen | OrganicChemical | 1,725 | 1,734 | preserve | 1779-1787 | 1779-1787 | T107 | patients | PatientOrDisabledGroup | 1,779 | 1,787 | A16 | CONCLUSIONS: According to the data of the recent EBCTG overview, an additional 20,000 lives could be saved worldwide each year if tamoxifen were given to all early breast cancer patients with hormone-sensitive disease, irrespective of age and disease stage, and for a minimum of five years. | 1583-1897 | 1,583 | 1,897 | CONCLUSIONS: According to the data of the recent EBCTG overview, an additional 20,000 lives could be saved worldwide each year if @SUBJECT$ were @PREDICAT$ to all early breast cancer @OBJECT$ with hormone-sensitive disease, irrespective of age and disease stage, and for a minimum of five years. |
Fact | preserve | 2065-2067 | 2065-2067 | T129 | in | TREATS | 2,065 | 2,067 | preserve | 1996-2005 | 1996-2005 | T122 | tamoxifen | OrganicChemical | 1,996 | 2,005 | preserve | 2111-2118 | 2111-2118 | T128 | disease | DiseaseOrSyndrome | 2,111 | 2,118 | A18 | Our study, involving a representative sample of physicians practicing in Italy, shows that tamoxifen is not used optimally, with a substantial under-use in younger women and women with node-negative disease. | 1898-2119 | 1,898 | 2,119 | Our study, involving a representative sample of physicians practicing in Italy, shows that @SUBJECT$ is not used optimally, with a substantial under-use @PREDICAT$ younger women and women with node-negative @OBJECT$ . |
Fact | preserve | 2092-2096 | 2092-2096 | T131 | with | PROCESS_OF | 2,092 | 2,096 | preserve | 2111-2118 | 2111-2118 | T128 | disease | DiseaseOrSyndrome | 2,111 | 2,118 | preserve | 2086-2091 | 2086-2091 | T126 | women | PopulationGroup | 2,086 | 2,091 | A19 | Our study, involving a representative sample of physicians practicing in Italy, shows that tamoxifen is not used optimally, with a substantial under-use in younger women and women with node-negative disease. | 1898-2119 | 1,898 | 2,119 | Our study, involving a representative sample of physicians practicing in Italy, shows that tamoxifen is not used optimally, with a substantial under-use in younger women and @OBJECT$ @PREDICAT$ node-negative @SUBJECT$ . |
Fact | preserve | 980-984 | 980-984 | T63 | with | PROCESS_OF | 980 | 984 | preserve | 985-1030 | 1022-1030 | T60 | non-insulin-dependent diabetes mellitus | DiseaseOrSyndrome | 985 | 1,030 | preserve | 971-979 | 971-979 | T59 | patients | PatientOrDisabledGroup | 971 | 979 | A1 | Fosinopril (10 mg/day) was administered over 12 weeks to 11 microalbuminuric patients with non-insulin-dependent diabetes mellitus (NIDDM). | 888-1039 | 888 | 1,039 | Fosinopril (10 mg/day) was administered over 12 weeks to 11 microalbuminuric @OBJECT$ @PREDICAT$ @SUBJECT$ (NIDDM). |
Uncommitted | preserve | 2013-2022 | 2013-2022 | T125 | reduction | DISRUPTS | 2,013 | 2,022 | preserve | 1963-1969 | 1963-1969 | T119 | VCAM-1 | AminoAcidPeptideOrProtein | 1,963 | 1,969 | preserve | 2032-2048 | 2032-2048 | T122 | microalbuminuria | DiseaseOrSyndrome | 2,032 | 2,048 | A2 | Whether decreased VCAM-1 expression is responsible for the observed reduction in microalbuminuria, deserves further investigation. | 1939-2081 | 1,939 | 2,081 | Whether decreased @SUBJECT$ expression is responsible for the observed @PREDICAT$ in @OBJECT$ , deserves further investigation. |
Fact | preserve | 1891-1893 | 1891-1893 | T117 | in | TREATS | 1,891 | 1,893 | preserve | 1885-1890 | 1885-1890 | T114 | ACE-I | PharmacologicSubstance | 1,885 | 1,890 | preserve | 1914-1937 | 1926-1937 | T116 | endothelial dysfunction | DiseaseOrSyndrome | 1,914 | 1,937 | A4 | This may represent a novel mechanism of action of ACE-I in diabetes-associated endothelial dysfunction. | 1829-1938 | 1,829 | 1,938 | This may represent a novel mechanism of action of @SUBJECT$ @PREDICAT$ diabetes-associated @OBJECT$ . |
Fact | preserve | 424-426 | 424-426 | T30 | in | LOCATION_OF | 424 | 426 | preserve | 427-435 | 427-435 | T27 | patients | PatientOrDisabledGroup | 427 | 435 | preserve | 373-406 | 396-406 | T26 | vascular cell adhesion molecule-1 | AminoAcidPeptideOrProtein | 373 | 406 | A5 | Recently ACE-I have been found to decrease plasma levels of circulating vascular cell adhesion molecule-1 (cVCAM-1) in patients with congestive heart failure. | 295-466 | 295 | 466 | Recently ACE-I have been found to decrease plasma levels of circulating @OBJECT$ (cVCAM-1) @PREDICAT$ @SUBJECT$ with congestive heart failure. |
Fact | preserve | 1232-1234 | 1232-1234 | T88 | in | ASSOCIATED_WITH | 1,232 | 1,234 | preserve | 1219-1224 | 1219-1224 | T76 | PAI-1 | AminoAcidPeptideOrProtein | 1,219 | 1,224 | preserve | 1235-1240 | 1235-1240 | T78 | NIDDM | DiseaseOrSyndrome | 1,235 | 1,240 | A6 | PAI-1 levels in NIDDM were similar to those in control subjects, whereas TPA levels were about 25% lower in patients than in control subjects (P = .013). | 1219-1384 | 1,219 | 1,384 | @SUBJECT$ levels @PREDICAT$ @OBJECT$ were similar to those in control subjects, whereas TPA levels were about 25% lower in patients than in control subjects (P = .013). |
Fact | preserve | 436-440 | 436-440 | T31 | with | PROCESS_OF | 436 | 440 | preserve | 441-465 | 458-465 | T28 | congestive heart failure | DiseaseOrSyndrome | 441 | 465 | preserve | 427-435 | 427-435 | T27 | patients | PatientOrDisabledGroup | 427 | 435 | A7 | Recently ACE-I have been found to decrease plasma levels of circulating vascular cell adhesion molecule-1 (cVCAM-1) in patients with congestive heart failure. | 295-466 | 295 | 466 | Recently ACE-I have been found to decrease plasma levels of circulating vascular cell adhesion molecule-1 (cVCAM-1) in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 132-136 | 132-136 | T13 | with | PROCESS_OF | 132 | 136 | preserve | 137-153 | 137-153 | T9 | microalbuminuria | DiseaseOrSyndrome | 137 | 153 | preserve | 123-131 | 123-131 | T8 | patients | PatientOrDisabledGroup | 123 | 131 | A8 | Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. | 0-154 | 0 | 154 | Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 335-343 | 335-343 | T29 | decrease | INHIBITS | 335 | 343 | preserve | 304-309 | 304-309 | T22 | ACE-I | PharmacologicSubstance | 304 | 309 | preserve | 373-406 | 396-406 | T26 | vascular cell adhesion molecule-1 | AminoAcidPeptideOrProtein | 373 | 406 | A11 | Recently ACE-I have been found to decrease plasma levels of circulating vascular cell adhesion molecule-1 (cVCAM-1) in patients with congestive heart failure. | 295-466 | 295 | 466 | Recently @SUBJECT$ have been found to @PREDICAT$ plasma levels of circulating @OBJECT$ (cVCAM-1) in patients with congestive heart failure. |
Fact | preserve | 227-236 | 227-236 | T19 | treatment | TREATS | 227 | 236 | preserve | 155-195 | 185-195 | T14 | Angiotensin converting enzyme inhibitors | PharmacologicSubstance | 155 | 195 | preserve | 277-293 | 277-293 | T18 | microalbuminuria | DiseaseOrSyndrome | 277 | 293 | A12 | Angiotensin converting enzyme inhibitors (ACE-I) are a mainstay for the treatment of heart failure, and of diabetic microalbuminuria. | 155-294 | 155 | 294 | @SUBJECT$ (ACE-I) are a mainstay for the @PREDICAT$ of heart failure, and of diabetic @OBJECT$ . |
Fact | preserve | 114-131 | 123-131 | T11 | diabetic patients | PROCESS_OF | 114 | 131 | preserve | 114-122 | 114-122 | T7 | diabetic | Finding | 114 | 122 | preserve | 123-131 | 123-131 | T8 | patients | PatientOrDisabledGroup | 123 | 131 | A13 | Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. | 0-154 | 0 | 154 | Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II @SUBJECT$ @PREDICAT$ @OBJECT$ with microalbuminuria. |
Fact | preserve | 1819-1821 | 1819-1821 | T111 | in | COEXISTS_WITH | 1,819 | 1,821 | preserve | 1802-1818 | 1802-1818 | T109 | microalbuminuria | DiseaseOrSyndrome | 1,802 | 1,818 | preserve | 1822-1827 | 1822-1827 | T110 | NIDDM | DiseaseOrSyndrome | 1,822 | 1,827 | A14 | In conclusion, fosinopril lowered cVCAM-1 levels along with microalbuminuria in NIDDM. | 1736-1828 | 1,736 | 1,828 | In conclusion, fosinopril lowered cVCAM-1 levels along with @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 954-979 | 971-979 | T62 | microalbuminuric patients | PROCESS_OF | 954 | 979 | preserve | 954-970 | 954-970 | T58 | microalbuminuric | DiseaseOrSyndrome | 954 | 970 | preserve | 971-979 | 971-979 | T59 | patients | PatientOrDisabledGroup | 971 | 979 | A16 | Fosinopril (10 mg/day) was administered over 12 weeks to 11 microalbuminuric patients with non-insulin-dependent diabetes mellitus (NIDDM). | 888-1039 | 888 | 1,039 | Fosinopril (10 mg/day) was administered over 12 weeks to 11 @SUBJECT$ @PREDICAT$ @OBJECT$ with non-insulin-dependent diabetes mellitus (NIDDM). |
Fact | preserve | 11-20 | 11-20 | T10 | decreases | INHIBITS | 11 | 20 | preserve | 0-10 | 0-10 | T1 | Fosinopril | OrganophosphorusCompound | 0 | 10 | preserve | 39-72 | 62-72 | T3 | vascular cell adhesion molecule-1 | AminoAcidPeptideOrProtein | 39 | 72 | A17 | Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. | 0-154 | 0 | 154 | @SUBJECT$ @PREDICAT$ levels of soluble @OBJECT$ in borderline hypertensive type II diabetic patients with microalbuminuria. |
Fact | preserve | 73-75 | 73-75 | T12 | in | LOCATION_OF | 73 | 75 | preserve | 123-131 | 123-131 | T8 | patients | PatientOrDisabledGroup | 123 | 131 | preserve | 39-72 | 62-72 | T3 | vascular cell adhesion molecule-1 | AminoAcidPeptideOrProtein | 39 | 72 | A18 | Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. | 0-154 | 0 | 154 | Fosinopril decreases levels of soluble @OBJECT$ @PREDICAT$ borderline hypertensive type II diabetic @SUBJECT$ with microalbuminuria. |
Fact | preserve | 227-236 | 227-236 | T19 | treatment | TREATS | 227 | 236 | preserve | 155-195 | 185-195 | T14 | Angiotensin converting enzyme inhibitors | PharmacologicSubstance | 155 | 195 | preserve | 246-259 | 252-259 | T16 | heart failure | DiseaseOrSyndrome | 246 | 259 | A20 | Angiotensin converting enzyme inhibitors (ACE-I) are a mainstay for the treatment of heart failure, and of diabetic microalbuminuria. | 155-294 | 155 | 294 | @SUBJECT$ (ACE-I) are a mainstay for the @PREDICAT$ of @OBJECT$ , and of diabetic microalbuminuria. |